Lee-Jah Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8026787/publications.pdf

Version: 2024-02-01

1040056 1199594 1,512 11 9 12 citations h-index g-index papers 12 12 12 2451 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science, 2013, 341, 1359-1365.	12.6	686
2	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	30.7	313
3	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, The, 2014, 384, 2046-2052.	13.7	206
4	Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect. Journal of Infectious Diseases, 2013, 208, 418-422.	4.0	117
5	Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study. Vaccine, 2015, 33, 4610-4617.	3.8	50
6	Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65†years of age: A phase 3 randomized clinical trial. Vaccine, 2019, 37, 5825-5834.	3.8	50
7	Blockade of peanut allergy with a novel Ara h 2–Fcγ fusion protein in mice. Journal of Allergy and Clinical Immunology, 2013, 131, 213-221.e5.	2.9	37
8	A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-IT, in healthy adolescents in the United States. Vaccine, 2020, 38, 3560-3569.	3.8	26
9	The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 1069-1077.	2.8	14
10	Introductory paper: High-dose influenza vaccine. Vaccine, 2021, 39, A1-A5.	3.8	6
11	Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6†months through†<18†years of age: A randomized controlled phase II dose-finding trial. Vaccine, 2021, 39, 1572-1582.	3.8	4